Search Results - "Sebio, Ana"

Extraskeletal myxoid condrosarcoma: A clinical case at Hospital Sant Pau.

Authors: Sebio, Ana¹ asebio@santpau.cat

Source: Cancer & Chemotherapy Reviews. 2022, Vol. 17 Issue 3, p37-40. 4p.

Quality of Life and Patient‐Reported Outcomes in Patients With Osteosarcoma: A Systematic Review.

Authors: Sebio, Ana Berger, Claire Tabone, Marie-Dominique et al.

Source: European Journal of Cancer Care. 4/2/2025, Vol. 2025, p1-19. 19p.

Surgical Management and Therapeutic Strategy of Uterine Sarcoma According to Histological Subtype and Staging: Updated Review and Recommendations.

Authors: Muñoz-Casares, Francisco Cristóbal Gómez-Barbadillo, José Álvarez-Álvarez, Rosa et al.

Source: Cancers. Jun2026, Vol. 18 Issue 12, p1870. 28p.

Exploring Dystrophin Expression and Mutations in the DMD and Dystrophin-Glycoprotein Complex Genes as Prognostic Factors in Leiomyosarcomas.

Authors: Salazar, Juliana Cerdà, Paula Artigas, Alícia et al.

Source: International Journal of Molecular Sciences. Jun2026, Vol. 27 Issue 12, p5290. 13p.

VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol.

Authors: Salazar, Juliana Arranz, María J. Martin-Broto, Javier et al.

Source: Pharmaceuticals (14248247). Dec2025, Vol. 18 Issue 12, p1855. 11p.

Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines.

Authors: Vaz-Salgado, Maria Angeles Valverde-Morales, Claudia Alvarez, Rosa et al.

Source: Cancers. Oct2025, Vol. 17 Issue 19, p3158. 29p.

The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region.

Authors: Sebio, Ana Paré, Laia Páez, David et al.

Source: Pharmacogenetics. Mar2013, Vol. 23 Issue 3, p142-147. 6p.

Role of Spatially Fractionated Radiotherapy (LATTICE) Treatment in Inoperable Bulky Soft-Tissue Sarcomas.

Authors: Majercakova, Katarina Aguilar, Natalia Tejedor Isern Verdum, Josep et al.

Source: Cancers. Feb2025, Vol. 17 Issue 4, p624. 11p.

Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol.

Authors: Salazar, Juliana Arranz, María J. Martin-Broto, Javier et al.

Source: Pharmaceutics. Dec2024, Vol. 16 Issue 12, p1585. 12p.

Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations.

Authors: Muñoz-Casares, Francisco Cristóbal Martín-Broto, Javier Cascales-Campos, Pedro et al.

Source: Cancers. Aug2024, Vol. 16 Issue 15, p2646. 28p.

CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas.

Authors: Virgili, Anna C. Salazar, Juliana Gallardo, Alberto et al.

Source: Diagnostics (2075-4418). Jun2024, Vol. 14 Issue 11, p1195. 11p.

Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial.

Authors: Palmerini, Emanuela Lopez Pousa, Antonio Grignani, Giovanni et al.

Source: Cancer (0008543X). Jan2025, Vol. 131 Issue 1, p1-14. 14p.

Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.

Authors: Serrano, César Vivancos, Ana López-Pousa, Antonio et al.

Source: BMC Cancer. 2/5/2020, Vol. 20 Issue 1, p1-12. 12p. 1 Diagram, 2 Charts, 3 Graphs.

Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium.

Authors: Baldi, Giacomo G. Giani, Claudia Ljevar, Silva et al.

Source: European Journal of Cancer. May2026, Vol. 238, pN.PAG-N.PAG. 1p.

Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy.

Authors: Virgili Manrique, Anna C. Salazar, Juliana Arranz, María Jesús et al.

Source: Journal of Personalized Medicine. Apr2022, Vol. 12 Issue 4, p618-618. 14p.

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.

Authors: Páez, David Tobeña, María Fernández-Plana, Julen et al.

Source: British Journal of Cancer. Jan2019, Vol. 120 Issue 2, p190-195. 6p. 1 Diagram, 5 Charts.

A Novel NFIX-STAT6 Gene Fusion in Solitary Fibrous Tumor: A Case Report.

Authors: Moura, David S. Díaz-Martín, Juan Bagué, Silvia et al.

Source: International Journal of Molecular Sciences. Jul2021, Vol. 22 Issue 14, p7514-7514. 1p.

Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan‐induced severe toxicity.

Authors: Riera, Pau Salazar, Juliana Virgili, Anna C. et al.

Source: British Journal of Clinical Pharmacology. Jun2018, Vol. 84 Issue 6, p1389-1392. 4p. 2 Charts.

Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients.

Authors: Riera, Pau Rodríguez-Santiago, Benjamín Lasa, Adriana et al.

Source: Cancers. Aug2020, Vol. 12 Issue 8, p2245-2245. 1p.

Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.

Authors: Stremitzer, Stefan Zhang, Wu Yang, Dongyun et al.

Source: Cancer (0008543X). Jun2015, Vol. 121 Issue 11, p1898-1905. 8p.